Discover Financial (NYSE:DFS) reported quarterly earnings of $3.77 per share which beat the analyst consensus estimate of $3.66 by 3.01 percent. This is a 3.57 percent increase over earnings of $3.64 per share from the same period last year. The company reported quarterly sales of $3.73 billion which beat the analyst consensus estimate of $3.66 billion by 1.97 percent. This is a 27.11 percent increase over sales of $2.94 billion the same period last year.
AstraZeneca Announced Tezspire Approved in Japan for Severe Asthma
AstraZeneca's Tezspire (tezepelumab) has been approved in Japan for the treatment of bronchial asthma in patients with severe or refractory disease in whom asthma symptoms cannot be controlled with mid- or high-dose inhaled corticosteroids and other long-term maintenance therapies.1
